HIV treatment drug honored as “Breakthrough of the Year”
The drug lenacapavir, developed by biopharmaceutical company Gilead Sciences, was honored by the American scientific magazine Science as “Breakthrough of the Year”.
On December 12, the American scientific magazine Science honored lenacapavir – a new generation injectable drug used to treat HIV-infected patients – as “Breakthrough of the Year”.
The drug lenacapavir, sold under the brand name Sunlenca, was developed by biopharmaceutical company Gilead Sciences.
This is a new generation antiviral drug, aimed at preventing the formation of the capsid – the protein shell that surrounds the genetic material of the HIV virus and whose main task is to protect the virus’s genome. withdraw.
Since 2022, the US Food and Drug Administration (FDA) has approved lenacapavir to treat patients with multidrug-resistant HIV infection.
Many HIV/AIDS researchers hope that the drug developed by the US biopharmaceutical company Gilead Sciences will have the effect of sharply reducing infection rates worldwide when used as a preventive treatment. room (PrEP).
